Search

Your search keyword '"Castaño‐Diez, Sandra"' showing total 12 results
Start Over Author "Castaño‐Diez, Sandra"
12 results on '"Castaño‐Diez, Sandra"'

1. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study

Author

Jiménez-Vicente, Carlos, Guardia-Torrelles, Ares, Pérez-Valencia, Amanda Isabel, Martínez-Roca, Alexandra, Castaño-Diez, Sandra, Guijarro, Francesca, Cortés-Bullich, Albert, Merchán, Beatriz, Triguero, Ana, Hernández, Isabel, Brillembourg, Helena, Munárriz, Daniel, Zugasti, Inés, Fernández-Avilés, Francesc, Diaz-Beyá, Marina, and Esteve, Jordi

Published
2024
Full Text
View/download PDF

2. Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome

Author

Guijarro, Francesca, López-Guerra, Monica, Morata, Jordi, Bataller, Alex, Paz, Sara, Cornet-Masana, Josep Maria, Banús-Mulet, Antònia, Cuesta-Casanovas, Laia, Carbó, Josep Maria, Castaño-Díez, Sandra, Jiménez-Vicente, Carlos, Cortés-Bullich, Albert, Triguero, Ana, Martínez-Roca, Alexandra, Esteban, Daniel, Gómez-Hernando, Marta, Álamo Moreno, José Ramón, López-Oreja, Irene, Garrote, Marta, Risueño, Ruth M., Tonda, Raúl, Gut, Ivo, Colomer, Dolors, Díaz-Beya, Marina, and Esteve, Jordi

Published
2023
Full Text
View/download PDF

3. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Author

Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Oñate, Guadalupe, Diaz-Beyá, Marina, Arnan, Montserrat, Tormo, Mar, Vives, Susana, de Llano, María Paz Queipo, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Garcia-Guiñon, Antonio, Salamero, Olga, Sampol, Antònia, Merchan, Brayan M., Bargay, Joan, Castaño-Díez, Sandra, Esteban, Daniel, Oliver-Caldés, Aina, Rivero, Andrea, Mozas, Pablo, López-Guerra, Mònica, Pratcorona, Marta, Zamora, Lurdes, Costa, Dolors, Rozman, Maria, Nomdedéu, Josep F., Colomer, Dolors, Brunet, Salut, Sierra, Jorge, and Esteve, Jordi

Published
2022
Full Text
View/download PDF

4. Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.

Author

Jiménez‐Vicente, Carlos, Charry, Paola, Castaño‐Diez, Sandra, Guijarro, Francesca, López‐Guerra, Mònica, Pérez‐Valencia, Amanda Isabel, Martinez‐Roca, Alexandra, Cortés‐Bullich, Albert, Munárriz, Daniel, Solano, Maria Teresa, Rosiñol, Laura, Carreras, Enric, Urbano‐Ispizua, Álvaro, Fernández‐Avilés, Francesc, Martinez, Carmen, Suárez‐Lledó, María, Díaz‐Beyá, Marina, Rovira, Montserrat, Salas, María Queralt, and Esteve, Jordi

Subjects
HEMATOPOIETIC stem cell transplantation, ACUTE myeloid leukemia, ALLOIMMUNITY, GRAFT versus host reaction, CELL transplantation
Abstract

Summary: European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new myeloid classifications published the same year. We have retrospectively assessed the prognostic value of the ELN 2022 in 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo‐HCT), including 99 in first complete response (CR1) from 2011 to 2021 in our centre. Adverse risk patients (Adv) presented inferior outcome in terms of overall survival (OS) and leukaemia‐free survival (LFS) (OS [p = 0.003], LFS [p = 0.02]), confirmed in multivariate analysis (hazard ratio [HR] for OS = 2.00, p = 0.037). These results were also seen in patients allografted in CR1. Further analysis identified a subgroup named adverse‐plus (AdvP), including complex karyotype, MECOM(EVI1) rearrangements and TP53 mutations, with worse outcomes than the rest of groups of patients, including the Adv (HR for OS: 3.14, p < 0.001, HR for LFS: 3.36, p < 0.001), with higher 2‐year cumulative incidence of relapse (p < 0.001). Notably, within this analysis, the outcome of Adv and intermediate patients were similar. These findings highlight the prognostic value of ELN 2022 in patients undergoing allo‐HCT, which can be improved by the recognition of a poor genetic subset (AdvP) within the Adv risk group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Next Generation Sequencing Study of clonal Evolution in AML Shows Mutations in RAS-MAPK Signaling Pathway as an Emergent Mechanism of Progression in Low-Intensity Treatments

Author

Jiménez-Vicente, Carlos, primary, Lopez-Guerra, Monica, additional, Pérez-Valencia, Amanda Isabel, additional, Munarriz, Daniel, additional, Guijarro, Francesca, additional, Castaño-Diez, Sandra, additional, Martinez-Roca, Alexandra, additional, Cortes-Bullich, Albert, additional, Cardus, Aina, additional, Esteban, Daniel, additional, Triguero, Ana, additional, Tovar, Natalia, additional, Hernandez, Isabel, additional, Colomer, Dolors, additional, Diaz-Beya, Marina, additional, and Esteve, Jordi, additional

Published
2024
Full Text
View/download PDF

7. Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF

Author

Jiménez-Vicente, Carlos, primary, Martínez-Roca, Alexandra, additional, Pomares, Helena, additional, Castaño-Diez, Sandra, additional, Guijarro, Francesca, additional, López-Guerra, Mònica, additional, Bataller, Alex, additional, Esteban, Daniel, additional, Cortés-Bullich, Albert, additional, Pérez-Valencia, Amanda Isabel, additional, Guardia-Torrelles, Ares, additional, Zugasti, Inés, additional, Rovira, Montserrat, additional, Fernández-Avilés, Francesc, additional, Colomer, Dolors, additional, Arnan, Montserrat, additional, Diaz-Beyá, Marina, additional, and Esteve, Jordi, additional

Published
2023
Full Text
View/download PDF

8. Risk Factors for Mortality in Hematopoietic Stem Cell Transplantation Recipients with Bloodstream Infection: Points To Be Addressed by Future Guidelines

Author

Puerta-Alcalde, Pedro, Chumbita, Mariana, Charry, Paola, Castaño-Díez, Sandra, Cardozo, Celia, Moreno-García, Estela, Marco, Francesc, Suárez-Lledó, Maria, Garcia-Pouton, Nicole, Morata, Laura, Fernández-Avilés, Francesc, Martínez-Roca, Alexandra, Rodríguez, Gerardo, Martínez, Jose A., Martínez, Carmen, Mensa, Josep, Urbano, Álvaro, Rovira, Montserrat, Soriano, Alex, and Garcia-Vidal, Carolina

Published
2021
Full Text
View/download PDF

10. Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Author

Castaño-Díez, Sandra, Zugasti, Ines, Calvo, Xavier, Schulz, Felicitas, Avendaño Pita, Alejandro, Mora, Elvira, Falantes, Jose Francisco, Azaceta, Gemma, Ibáñez, Mariam, Chen, Tzu, Notario, Cristina, Amer Salas, Neus, López-Guerra, Mònica, Jimenez-Vicente, Carlos, Esteban, Daniel, Guijarro, Francesca, Álamo Moreno, José Ramón, Cortés-Bullich, Albert, Munárriz, Daniel, Torrecillas-Mayayo, Víctor, Triguero, Ana, Tovar, Natalia, Martínez-Roca, Alexandra, Merchán Muñoz, Beatriz, Carcelero, Esther, Germing, Ulrich, Betz, Beate, Rozman, María, Arenillas, Leonor, Zamora, Lurdes, Diez-Campelo, Maria, Xicoy, Blanca, Esteve, Jordi, and Díaz-Beyá, Marina

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results